Profile data is unavailable for this security.
About the company
Impact Biomedical Inc. is a human healthcare company and is a wholly owned subsidiary of DSS, Inc. The Company, through the utilization of its intellectual property rights, or through investment in, or through acquisition of companies in the bio health and biomedical fields, focuses on the advancement of drug discovery and prevention, inhibition, and treatment of neurological, oncological, and immune related diseases. The Company is also developing open-air defense initiatives, which curb transmission of air-borne infectious diseases, such as tuberculosis and influenza. The Company, through its subsidiary, Global BioLife, Inc., focuses on research in four main areas: the Linebacker project, which develops a universal therapeutic drug platform; a new sugar substitute called Laetose; a multi-use fragrance called 3F (Functional Fragrance Formulation), which is a mosquito fragrance product; and Equivir/Nemovir, a blend of natural polyphenols designed as an antimicrobial medication.
- Revenue in USD (TTM)0.00
- Net income in USD1.16m
- Incorporated2018
- Employees1.00
- LocationImpact Biomedical Inc1400 Broadfield Blvd., Suite 130HOUSTON 77084United StatesUSA
- Phone+1 (585) 232-1500
- Websitehttps://www.impactbiomedinc.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Eterna Therapeutics Inc | 598.00k | -44.95m | 27.34m | 8.00 | -- | -- | -- | 45.72 | -8.31 | -8.31 | 0.1105 | -8.39 | 0.0199 | -- | 0.6093 | 74,750.00 | -149.86 | -169.05 | -222.51 | -223.00 | 72.91 | -- | -7,513.88 | -682.61 | -- | -5.43 | -- | -- | -- | -68.89 | 11.84 | -- | -58.86 | -- |
| Hookipa Pharma Inc | 50.00m | -43.37m | 27.73m | 151.00 | -- | 0.3861 | -- | 0.5545 | -4.11 | -4.11 | 4.24 | 5.96 | 0.3653 | -- | 100.10 | 331,119.20 | -31.69 | -41.63 | -42.40 | -50.26 | -- | -- | -86.74 | -366.65 | -- | -- | 0.00 | -- | 41.27 | 21.41 | -25.67 | -- | 14.11 | -- |
| Longeveron Inc | 1.85m | -27.37m | 27.74m | 23.00 | -- | 1.08 | -- | 14.98 | -6.67 | -6.67 | 0.2962 | 1.73 | 0.0892 | -- | 7.78 | 80,521.74 | -86.28 | -63.15 | -102.27 | -75.68 | 73.06 | 33.70 | -967.49 | -441.02 | -- | -- | 0.00 | -- | -41.98 | -19.78 | -17.92 | -- | 26.80 | -- |
| SAB Biotherapeutics Inc | 1.51m | -45.57m | 28.33m | 57.00 | -- | 0.7678 | -- | 18.73 | -5.84 | -5.84 | 0.1753 | 4.00 | 0.0368 | -- | 31.17 | 26,539.12 | -110.96 | -- | -142.16 | -- | -- | -- | -3,012.26 | -- | -- | -- | 0.0856 | -- | -90.63 | -- | -125.14 | -- | -- | -- |
| RenovoRx Inc | 0.00 | -9.16m | 29.03m | 8.00 | -- | 4.11 | -- | -- | -0.572 | -0.572 | 0.00 | 0.2946 | 0.00 | -- | -- | 0.00 | -135.25 | -- | -180.14 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -3.47 | -- | -- | -- |
| Chemomab Therapeutics Ltd - ADR | 0.00 | -14.40m | 29.61m | 20.00 | -- | 1.85 | -- | -- | -0.9868 | -0.9868 | 0.00 | 0.8654 | 0.00 | -- | -- | 0.00 | -64.98 | -- | -83.24 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 12.39 | -- | -- | -- |
| Hcw Biologics Inc | 3.50m | -37.33m | 29.79m | 45.00 | -- | -- | -- | 8.52 | -1.00 | -1.00 | 0.0939 | -0.2636 | 0.1125 | -- | 5.13 | 77,688.45 | -120.09 | -- | -279.71 | -- | 32.41 | -- | -1,067.83 | -- | -- | -93.78 | 4.52 | -- | -57.72 | -- | -67.74 | -- | -- | -- |
| Impact Biomedical Inc | 0.00 | 1.16m | 30.12m | 1.00 | 25.98 | 0.9633 | 13.58 | -- | -0.2094 | -0.2094 | 0.00 | 2.72 | 0.00 | -- | -- | 0.00 | 2.39 | -- | 3.04 | -- | -- | -- | -- | -- | -- | -- | 0.189 | -- | -100.00 | -- | 38.51 | -- | -- | -- |
| Surrozen Inc | 10.00m | -44.44m | 30.22m | 42.00 | -- | 5.33 | -- | 3.02 | -17.05 | -17.05 | 3.81 | 1.74 | 0.1961 | -- | 1.41 | 238,095.20 | -87.16 | -- | -99.66 | -- | -- | -- | -444.38 | -- | -- | -1.43 | 0.00 | -- | -100.00 | -- | -19.55 | -- | -- | -- |
| Clene Inc. | 421.00k | -36.02m | 30.40m | 82.00 | -- | -- | -- | 72.22 | -5.58 | -5.58 | 0.0652 | -0.6016 | 0.0092 | 0.7759 | 13.16 | 5,134.15 | -78.31 | -39.43 | -136.18 | -47.32 | 78.62 | -- | -8,556.77 | -5,261.20 | 0.8213 | -10.15 | 1.30 | -- | 38.27 | -- | -65.47 | -- | -- | -- |
| Promis Neurosciences Inc | 0.00 | -563.35k | 31.22m | 6.00 | -- | 4.29 | -- | -- | -0.1931 | -0.1931 | 0.00 | 0.2225 | 0.00 | -- | -- | 0.00 | -2.66 | -144.28 | -3.77 | -262.23 | -- | -- | -- | -2,271,047.00 | -- | -- | 0.00 | -- | -- | -- | 26.85 | -- | -- | -- |
| Lantern Pharma Inc | 0.00 | -19.09m | 31.81m | 21.00 | -- | 1.20 | -- | -- | -1.77 | -1.77 | 0.00 | 2.47 | 0.00 | -- | -- | 0.00 | -48.91 | -28.83 | -52.88 | -30.17 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -11.93 | -- | -- | -- |
| Citius Pharmaceuticals Inc | 0.00 | -39.77m | 31.89m | 22.00 | -- | 0.3482 | -- | -- | -0.2443 | -0.2443 | 0.00 | 0.4741 | 0.00 | -- | -- | 0.00 | -36.91 | -30.26 | -39.00 | -32.11 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -0.1589 | -- | -- | -- |
| Estrella Immunopharma Inc | 0.00 | -8.82m | 32.21m | -- | -- | 43.15 | -- | -- | -0.2378 | -0.2378 | 0.00 | 0.0206 | 0.00 | -- | -- | -- | -56.73 | -- | -163.06 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 34.21 | -- | -- | -- |
| LianBio - ADR | 0.00 | -87.98m | 32.42m | 163.00 | -- | 0.1589 | -- | -- | -0.8195 | -0.8195 | 0.00 | 1.89 | 0.00 | -- | -- | 0.00 | -28.62 | -- | -35.22 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 43.82 | -- | -- | -- |
| Grace Therapeutics, Inc | 0.00 | -11.61m | 32.75m | 32.00 | -- | 0.5835 | -- | -- | -1.08 | -1.08 | 0.00 | 5.54 | 0.00 | -- | -- | -- | -16.17 | -31.68 | -16.64 | -33.95 | -- | -- | -- | -56,271.43 | -- | -- | 0.00 | -- | -- | -- | 69.71 | -- | -47.16 | -- |
Data as of Nov 22 2024. Currency figures normalised to Impact Biomedical Inc's reporting currency: US Dollar USD
0.58%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Ferguson Wellman Capital Management, Inc.as of 30 Sep 2024 | 36.36k | 0.32% |
| Jane Street Capital LLCas of 30 Sep 2024 | 13.36k | 0.12% |
| HRT Financial LP (US)as of 30 Sep 2024 | 12.50k | 0.11% |
| BofA Securities, Inc.as of 30 Sep 2024 | 2.60k | 0.02% |
| Barclays Capital Securities Ltd.as of 30 Sep 2024 | 1.12k | 0.01% |
| Morgan Stanley & Co. LLCas of 30 Sep 2024 | 58.00 | 0.00% |
| Wells Fargo Securities LLCas of 30 Sep 2024 | 29.00 | 0.00% |
| UBS Financial Services, Inc.as of 30 Sep 2024 | 3.00 | 0.00% |
| Group One Trading LLCas of 30 Sep 2024 | 1.00 | 0.00% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
